Transgene starts lymphoma drug trial
In the first stage of the trial, a group of 13 patients with relapsing CBCL will be enrolled at centers in the US, France and Switzerland. If the
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.